Jazz Phar­ma­ceu­ti­cals gets FDA OK for cat­a­plexy drug as it pre­pares to re­place old cash cow

Fol­low­ing an FDA ap­proval just last month for its small cell lung can­cer drug, Jazz Phar­ma­ceu­ti­cals keeps on rolling.

The Irish phar­ma an­nounced Wednes­day that Xy­wav, treat­ing cat­a­plexy and ex­ces­sive day­time sleepi­ness as­so­ci­at­ed with nar­colep­sy in pa­tients old­er than sev­en years, has been giv­en the green light by US reg­u­la­tors. This is the third FDA ap­proval grant­ed to Jazz in the last 16 months and the sec­ond nar­colep­sy-re­lat­ed drug af­ter Sunosi was OK’ed in March 2019.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER